The 7 most recent market catalysts affecting $PPCB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 55
Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
This 8-K filing from Propanc Biopharma announces a comparative analysis of its lead drug candidate, PRP, against Erasca's ERAS-0015, specifically in the context of pancreatic ducta…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 55
Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015
Propanc Biopharma (PPCB) is attempting to position its lead candidate, PRP, within the rapidly evolving landscape of RAS-targeted cancer therapies. The filing details the strong cl…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Propanc Biopharma (PPCB) experienced a massive stock surge due to the release of highly positive preclinical and early translational data for its pancreatic cancer drug, PRP. The d…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.
The announcement of positive preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma is a significant positive catalyst for Propanc Biopharma (PPCB). T…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Propanc Biopharma Says Preclinical PRP Data In Pancreatic Cancer Models Showed Greater Than 90% Mean Tumor Growth Inhibition, More Than 2.5-Fold Median Survival Extension
The headline is a significant corporate catalyst for Propanc Biopharma (PPCB) due to highly positive preclinical results for its pancreatic cancer treatment. While preclinical data…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for PRP showing >90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models.
This headline represents a significant corporate catalyst for Propanc Biopharma, driving its shares higher due to promising preclinical data. The >90% tumor growth inhibition and s…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 55
Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories
Propanc Biopharma announced the publication of research findings in a peer-reviewed journal, 'Microbial Cell Factories,' detailing the evaluation of recombinant trypsinogen and chy…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.